Basket | Login

 
 
 
 

Clinical trials by country

Phase III trials

Austria

  1. EMBARK

Bulgaria

  1. 17-AVP-786-305

Belgium

  1. EMBARK
  2. INFRONT-3

Czech Republic

  1. 17-AVP-786-305

Denmark

  1. EMBARK

Finland

  1. EMBARK

France

  1. INFRONT-3 (planned)
  2. LO-MAPT
  3. 17-AVP-786-305

Germany

  1. ANAVEX®2-73-AD-004
  2. EMBARK
  3. INFRONT-3

Hungary

  1. 17-AVP-786-305

Italy

  1. EMBARK
  2. INFRONT-3
  3. 17-AVP-786-305

Netherlands

  1. ANAVEX®2-73-AD-004
  2. EMBARK
  3. INFRONT-3

Poland

  1. EMBARK
  2. 17-AVP-786-305

Portugal

  1. EMBARK
  2. INFRONT-3

Spain

  1. EMBARK
  2. INFRONT-3
  3. 17-AVP-786-305

Sweden

  1. EMBARK
  2. INFRONT-3

Switzerland

  1. EMBARK
  2. INFRONT-3

UK

  1. ANAVEX®2-73-AD-004
  2. EMBARK
  3. INFRONT-3
  4. NorAD
  5. 17-AVP-786-305

 

 
 

Last Updated: Wednesday 21 April 2021

 

 
  • Acknowledgements

    Alzheimer Europe's Clinical Trial Watch received funding under an operating grant from the European Union’s Health Programme (2014–2020).
  • European Union
 
 

Options